Key result
Loss of heterozygosity at 17p13 was found in 74% of adrenocortical carcinomas compared with 14% of adrenocortical adenomas, with ACADVL and ALOX15B expression significantly down-regulated in ACCs.
Population
37 paired blood and adrenocortical tumor samples for LOH analysis, and 50 samples for RT-PCR analysis.
Design
Other
Authors
Loading...
May aid ACC-adenoma differentiation; leaves open prospective validation before clinical adoption.
Observational
Absolute Event Rate: 74% vs 14%
ACADVL and ALOX15B expression levels on 17p13 may serve as molecular discriminators between adrenocortical carcinomas and adenomas.
Soon et al. (2008) conducted an observational in Adrenocortical tumors. Adrenocortical carcinoma vs. Adrenocortical adenoma was evaluated on Loss of heterozygosity (LOH) at 17p13. Loss of heterozygosity at 17p13 was found in 74% of adrenocortical carcinomas compared with 14% of adrenocortical adenomas, with ACADVL and ALOX15B expression significantly down-regulated in ACCs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: